Introduction
The complement system carries out various tasks as part of innate immunity by recognizing and eliminating pathogens. However, the inappropriate activation of the system has been implicated in kidney disease. Recently, its extra-immunological role in metabolic disease has come to the foreground and has received increasing scientific attention. Complement components are overproduced by adipocytes and are activated in association with obesity and dyslipidaemia. In this review, we discuss recent advances in identifying the extraimmunological role of the complement system in the development and progression of diabetic kidney disease.
Discussion
The author has referenced some of his own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.
Activation of complement pathways in physiology and pathology
The complement cascade can be activated through three different pathways: the classical, alternative and lectin pathways. The three pathways are activated in a sequential manner, with activation of one component leading to activation of the next. The classical pathway is initiated by recognition of the antigen-antibody complex on binding with C1q. This leads to conformational changes resulting in the activation of C1r and C1s, and the formation of C1 complex. Then, C1 complex activates C4 and C2 leading to the formation of C3 convertase, C4b2a. Activation of the alternative pathway depends on spontaneous hydrolysis of C3 in plasma leading to the formation of C3(H 2 O), which can bind to Factor B. Subsequent activation by Factor D results in the formation of C3(H 2 O)Bb. This complex constantly cleaves another C3 molecule in plasma to C3a and C3b very slowly. In the physiological condition, C3b is protected by regulatory proteins such as Factor H and Factor I. However, C3bBb is formed and stabilized by Properdin under pathological conditions. Activation of the lectin pathway occurs in response to recognition of mannosebinding lectin (MBL) in various carbohydrate ligands. This induces activation of MBL-associated serin protease (MASP)-1 and MASP-2. MASP-2 cleaves C4 and subsequently C2, which leads to the formation of C3 convertase, C4b2a. These three pathways converge in the activation of C3 at the membrane of the target organ. Sufficient activation of C3 leads to the activation of C5 and a subsequent terminal complement pathway, resulting in the formation of membrane attack complex (MAC) and tissue injury 1, 2 . A simplified diagram of the complement activation system is shown in Figure 1 . In patients with type 2 diabetes (T2DM), the plasma levels of complement components are elevated, and the alternative pathway is activated in association with obesity and dyslipidaemia 3, 4 .
Extra-immunological role of complement activation in diabetic nephropathy
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The traditional role of complement activation in kidney injury
The major function of the complement system has been thought to be recognition and elimination of exogenous antigens or abnormally produced auto-antibodies. Streptococcal antigen in acute proliferative glomerulonephritis, C3 nephritic factor in membrano-proliferative glomerulonephritis, and antigenantibody complex in lupus nephritis and membranous nephropathy are well-known complement-implicated mechanisms in the establishment of glomerular injury 5, 6 . IgA and C3 are deposited in the glomerular mesangium in patients with IgA nephropathy, suggesting IgAinitiated activation of the alternative complement pathway 7 . These abnormalities in the pathogenesis of various primary glomerular diseases and autoimmune diseases with renal involvement have been discussed. In metabolic diseases such as diabetes mellitus, the implication of complement activation has been poorly appreciated in the development of kidney involvement. Recently, the complement system has been shown to be causally involved in tissue injury in patients with diabetic nephropathy including obesity, dyslipidaemia and hypertension as well as in patients with autoimmune or infective diseases 8, 9 .
Crosstalk between the immune system and metabolism in tissue
Several factors in the immune response such as the complement system have been implicated in the crosstalk between the immune system and metabolism 10, 11 . Recent data suggest that C3 plays a role in metabolic disorders 12, 13 . The plasma C3 level is associated with the development of T2DM and several risk factors such as obesity, dyslipidaemia, and insulin resistance 14, 15 . The link between complement activation and metabolic syndrome is substantiated by the observations that adipose tissue secretes complement components. Several adipocyte-derived cytokines activate proinflammatory cytokines and act on macrophages, which results in tissue injury in the diabetic kidney 16, 17 .
Role of complement activation in diabetic vascular complications
During the course of T2DM, the following pathophysiological states are 
Atherosclerosis and Hypertension
The C5b-9n assembly is deposited in atherosclerotic lesions, and sublytic C5b-9n assembly induces smooth muscle cell and endothelial cell activation and proliferation 18, 19 . These data suggest that activation of the complement system plays an important role in the formation and the rupture of atherosclerotic plaque and arteriosclerotic hypertension due to smooth muscle hypertrophy. Since smooth muscle cells do not express the complement inhibitory molecule (CD59), they represent a possible important target for complement activation 20 . Experimental studies using atherosclerotic rabbits have shown that C5b-9n deposition in the arterial wall preceded monocyte infiltration and foam cell formation 21 .
Dyslipidaemia and Inflammation
Cholesterol accumulation regulates genes implicated in complement activation. Loading sterol into macrophages regulates levels of complement proteins 22 . In the postprandial hyperchylomicronemic condition, the alternative complement pathway is activated near adipose tissue 3 . Complement activation can promote systemic inflammation. A simplified diagram of the complement activation induced by chylomicron is shown in Figure 2 . vanGreevenbroek et al. 15 reported that complement gene expression was up-regulated in patients with obesity and dyslipidaemia. Such up-regulation may subsequently influence downstream processes, including macrophage infiltration into adipose tissue and adipocyte insulin resistance. Adipocytokines crosstalk with proinflammatory cytokines and act to promote macrophage accumulation, which results in inflammation of the kidney 23 .
Obesity and Insulin resistance
Active adipocytes overproduce complement components in patients with obesity. Serum C3 correlated with insulin resistance and homeostasis model assessment of insulin resistance 16 . The chylomicronactivated alternative pathway overproduces C3a 3 . C3a receptor (C3aR) expressed in adipose tissue is upregulated after ingesting ahigh-fat diet 13 . Interruption of the C3a-C3aR axis in a C3aR-/-mouse prevented dietinduced insulin resistance. Insulin is directly involved in nitric oxide production, and insulin resistance is associated with endothelial dysfunction 24 . Both obesity and the postprandial hyperchylomicronemic condition induce complement activation and acylation stimulating protein (ASP) production. Signalling of ASP via C5a receptor-like 2 may contribute to adipose tissue inflammation and metabolism 25 . A simplified diagram of the complement system and insulin resistance is shown in Figure 3 .
Ischemia/reperfusion injury and Reactive oxygen species (ROS)
Atherosclerotic persistent ischemia and reperfusion of peripheral micro vessels in organs induce inflammation that can lead to tissue injury. Complement activation has been known to play a role in the inflammation and tissue injury associated with ischemia/reperfusion injury in the kidney 26 . Intra-cellular production of reactive oxygen species in endothelial cells during ischemia/reperfusion may initiate nuclear factor-kappa B activation resulting in complement activation 27 . ROS generation is also a candidate major factor leading to diabetic nephropathy.
Coagulation and Endothelial injury
The coagulation cascade is able to activate the complement pathway. On the other hand, the coagulation cascade is activated by the complement system. MASP-2 plays a role in the activation of thrombin and subsequent generation of the fibrin mesh 28 . C5a can trigger the release of the endothelial surface proteoglycan heparansulphate, independent of the formation of MAC 29 . Wang et al. 30 reported that the lectin-like domain of thrombomodulin ameliorates diabetic nephropathy via complement inhibition. Even though coagulation and the complement system are two distinct systems, these networks have several common functional attributes in the progression of renal injury.
Conclusion
Complement activation plays a role in the progression of diabetic renal injury by an extra-immunological mechanism besides the traditional immunological mechanism. Especially, metabolic implications in renal endothelial injury have been appreciated and have received increasing attention in T2DM patients with obesity and dyslipidaemia. MAC contributes to the formation of atherosclerotic plaque, and ASP contributes to the expression of insulin resistance and tissue inflammation, resulting in renal microvascular complication. In patients with T2DM with obesity, activated adipocytes overproduce complement components such as C3 and Factor B. Chylomicron activates the alternative complement pathway by regulating the effect of Factor H. During this process, C3 is spontaneously and continuously converted to C3a and C3b. C3b excites the terminal complement pathway and forms membrane attack complexes (MACs), which contribute to the formation of atherosclerotic plaque. C3a contributes to the induction of insulin resistance in adipocytes and macrophages, and inflammation in vascular endothelial cells. C3a is immediately converted to acylation stimulating protein (ASP), which leads to the induction of triacylglycerol production and obesity. The complement system is a versatile player. Further studies are warranted to identify in more detail components of the complement system as possible targets for the prevention of diabetic nephropathy.
